ONCOLOGY: Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes

Audio Journal of Oncology, December 9th, 2007 Reporting from: American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes PIERRE FENAUX, Paris 13 University REFERENCE: ABSTRACT 817, ASH 2007 Results from a phase III study presented at ASH suggest that the hypomethylating agent azacitidine should be the new standard of care for patients with high-risk MDS. Pierre Fenaux of Paris 13 University gave the details to Derek Thorne.

You can listen to ONCOLOGY: Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes online on Radio and Podcast. Open the player on this page to stream the available audio.

ONCOLOGY: Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes is an episode from Audio Medica News - Medical News Interviews by Audio Medica.

This episode is 00:03:52 long.

This episode was published on Dec 10, 2007.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from Audio Medica News - Medical News Interviews when more episodes are available from the podcast feed.